Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMAVANSERIN vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist and antagonist, with no affinity for dopamine receptors, modulating glutamate and dopamine signaling in the cortex and striatum.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Treatment of hallucinations and delusions associated with Parkinson's disease psychosis (FDA-approved)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
34 mg orally once daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 50 hours, allowing once-daily dosing; steady state reached in about 2 weeks.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily metabolized by CYP3A4 and CYP3A5, with minor contributions from CYP2J2 and CYP2D6. The major metabolite is N-desmethylpimavanserin, which is pharmacologically active.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily hepatic metabolism, with approximately 60% excreted in feces and 20% in urine as metabolites; less than 5% excreted as unchanged drug.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 95% bound to plasma proteins, primarily albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution is approximately 400 L (about 4.7 L/kg), indicating extensive extravascular distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is approximately 20% due to extensive first-pass metabolism.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to increased exposure and risk of QT prolongation.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Safety and efficacy not established in pediatric patients (<18 years). No dosing recommendation.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment; use caution due to potential increased sensitivity and risk of QT prolongation. Monitor renal function and electrolytes.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No FDA boxed warning.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of QT interval prolongation; avoid use in patients with known QT prolongation or with drugs that prolong QT interval.,Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).,May cause somnolence, orthostatic hypotension, and gastrointestinal effects.,Gradual dose titration recommended to minimize adverse effects.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to pimavanserin or any of its components.,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased exposure and risk of QT prolongation.,Concomitant use with strong CYP3A4 inducers (e.g., rifampin) may reduce efficacy.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit and grapefruit juice due to potential for increased pimavanserin exposure and QT prolongation risk. No other significant food interactions reported.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Pimavanserin is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 8 times the maximum recommended human dose. However, because animal studies are not always predictive of human response, pimavanserin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester risks are unknown; second and third trimester risks are not characterized. Use caution.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
It is not known whether pimavanserin is excreted in human milk. The molecular weight (approx. 540 Da) suggests possible excretion. No data on M/P ratio. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No pharmacokinetic studies in pregnant women are available. Dose adjustments are not established. Use the lowest effective dose if treatment is deemed necessary during pregnancy.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Pimavanserin is a 5-HT2A inverse agonist approved for Parkinson's disease psychosis. It does not worsen motor symptoms due to lack of dopamine receptor affinity. QT prolongation risk is dose-dependent; monitor ECG at baseline and after dose changes. Avoid use in patients with dementia-related psychosis due to increased mortality risk. A 1-week washout prior to initiation is recommended if switching from other antipsychotics. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Avoid grapefruit juice as it may increase drug levels.,Report any irregular heartbeat, fainting, or dizziness.,Do not drive or operate heavy machinery until effect on coordination is known.,Take this medication with or without food exactly as prescribed.,Do not stop abruptly without consulting your doctor.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Pimavanserin, a serotonin 5-HT2A receptor inverse agonist, may reduce the therapeutic efficacy of apomorphine, a non-ergoline dopamine agonist used for Parkinson's disease. By antagonizing 5-HT2A receptors, pimavanserin could counteract the dopamine-mediated effects of apomorphine, potentially leading to worsened motor control and reduced clinical benefit. This interaction may result in increased Parkinsonian symptoms and decreased response to apomorphine rescue therapy."
"Pimavanserin, a serotonin 5-HT2A receptor inverse agonist, may antagonize the effects of levodopa by blocking 5-HT2A receptors on dopaminergic neurons, potentially reducing the therapeutic efficacy of levodopa in treating Parkinson's disease. This interaction can lead to worsening of motor symptoms and decreased clinical response to levodopa therapy."
"The therapeutic efficacy of Rotigotine can be decreased when used in combination with Pimavanserin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMAVANSERIN vs ABSTRAL, answered by our medical review team.
PIMAVANSERIN is a Serotonin Inverse Agonist that works by Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist and antagonist, with no affinity for dopamine receptors, modulating glutamate and dopamine signaling in the cortex and striatum.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMAVANSERIN and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMAVANSERIN is: 34 mg orally once daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMAVANSERIN and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMAVANSERIN is classified as Category A/B. Pimavanserin is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm w. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.